Copyright © 2024 广州源井生物科技有限公司 版权所有
粤ICP备19080093号
Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients
Acetate reprogrammes tumour metabolism and promotes PD-L1 expression and immune evasion by upregulating c-Myc
Generation of iPSC-derived human venous endothelial cells for the modeling of vascular malformations and drug discovery
Intelligent Nano‐Cage for Precision Delivery of CRISPR‐Cas9 and ACC Inhibitors to Enhance Antitumor Cascade Therapy Through Lipid Metabolism Disruption
Adaptive Design of Nanovesicles Overcoming Immunotherapeutic Limitations of Chemotherapeutic Drugs through Poliovirus Receptor Blockade.
Cell surface patching via CXCR4-targeted nanothreads for cancer metastasis inhibition